VOR BIOPHARMA INC

NASDAQ: VOR (Vor Biopharma Inc.)

Kemas kini terakhir: 12 Dec, 5:54PM

12.51

0.38 (3.13%)

Penutupan Terdahulu 12.13
Buka 11.99
Jumlah Dagangan 3,379,933
Purata Dagangan (3B) 1,385,021
Modal Pasaran 274,102,016
Harga / Buku (P/B) 3.14
Julat 52 Minggu
2.62 (-79%) — 65.80 (425%)
Tarikh Pendapatan 13 Nov 2025
EPS Cair (TTM) -1.51
Jumlah Hutang/Ekuiti (D/E MRQ) 46.59%
Nisbah Semasa (MRQ) 3.88
Aliran Tunai Operasi (OCF TTM) -100.26 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -61.85 M
Pulangan Atas Aset (ROA TTM) -55.25%
Pulangan Atas Ekuiti (ROE TTM) -125.43%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Vor Biopharma Inc. Menaik Menaik

AISkor Stockmoo

1.0
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata 1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
VOR 274 M - - 3.14
COGT 6 B - - 30.40
CGON 3 B - - 4.46
HRMY 2 B - 11.93 2.61
PGEN 1 B - - 36.47
TYRA 1 B - - 4.30

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 43.00%
% Dimiliki oleh Institusi 46.77%
Julat 52 Minggu
2.62 (-79%) — 65.80 (425%)
Julat Harga Sasaran
9.00 (-28%) — 64.00 (411%)
Tinggi 64.00 (Baird, 411.59%) Beli
Median 36.00 (187.77%)
Rendah 9.00 (Wedbush, -28.06%) Pegang
Purata 36.25 (189.77%)
Jumlah 3 Beli, 1 Pegang
Harga Purata @ Panggilan 15.15
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
JP Morgan 19 Dec 2025 40.00 (219.74%) Beli 12.41
09 Dec 2025 43.00 (243.73%) Beli 10.72
Wedbush 25 Nov 2025 9.00 (-28.06%) Pegang 7.96
HC Wainwright & Co. 14 Nov 2025 32.00 (155.80%) Beli 10.01
29 Oct 2025 52.00 (315.67%) Beli 25.50
Baird 15 Oct 2025 64.00 (411.59%) Beli 30.22

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
15 Dec 2025 Pengumuman Vor Bio Announces $150 Million Private Placement
13 Nov 2025 Pengumuman Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10 Nov 2025 Pengumuman Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
10 Nov 2025 Pengumuman Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
08 Nov 2025 Pengumuman Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
07 Nov 2025 Pengumuman Vor Bio to Participate in Upcoming Investor Conferences
03 Nov 2025 Pengumuman Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
31 Oct 2025 Pengumuman Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Oct 2025 Pengumuman Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
22 Oct 2025 Pengumuman Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
17 Oct 2025 Pengumuman Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
16 Oct 2025 Pengumuman Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
14 Oct 2025 Pengumuman Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
03 Oct 2025 Pengumuman Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Sep 2025 Pengumuman Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
23 Sep 2025 Pengumuman Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda